Soon, Congress may vote on whether to require the Medicare system to negotiate lower prices for medicines taken by millions of seniors enrolled in Medicare Part D prescription drug plans.That change and others might save some seniors a lot of m
In a new study on Body dysmorphic disorder (BDD) - a distressing or impairing preoccupation with an imagined or slight defect in one's appearance - researchers from Bradley Hospital and Brown Medical School found that individuals who are concerned abou
A pattern of micro molecules can distinguish pancreatic cancer from normal and benign pancreatic tissue, new research suggests. The study examined human pancreatic tumor tissue and compared it to nearby normal tissue and control tissue for leve
New research shows that a recently discovered enzyme that destroys the messenger RNA (mRNA) for some proteins can also help to protect the mRNA during times of stress. The response might help cancer cells survive chemotherapy and radiation therapy.
A new study using mastectomy tissue shows that precancerous changes can occur in normal-appearing areas of the breast as distant as two inches from a tumor's edge. The findings, while preliminary, might have important implications for identifyi
An important cancer-related gene may play a critical role in the development of the placenta, the organ that controls nutrient and oxygen exchange between a mother and her fetus during pregnancy, and perhaps in miscarriages. Those conclusions c
Researchers at Wake Forest University School of Medicine are the first to report that in animal studies, a common diabetes drug prevents the memory and learning problems that cancer patients often exper
Combining synthetic chemistry techniques with a knowledge of the properties and actions of enzymes, scientists have been able to produce an exciting class of anti-cancer drugs originally isolated from blue-green algae. This accomplishment is ex
In a surprise finding, scientists have discovered that histamine, the inflammatory compound released during allergic reactions that causes runny nose, watery eyes, and wheezing, can be produced in large amounts in the lung by neutrophils, the white blo
Neuren Pharmaceuticals Ltd has successfully completed a Phase 1 safety and tolerability trial of its second lead candidate, NNZ-2566, which is being developed to treat traumatic brain injury (TBI)
Date: Tuesday, 14-Nov-2006
Results of the two largest studies on hyponatremia, SALT-1 and SALT-2, presented Nov. 14 at the American Heart Association's Scientific Sessions in Chicago, found that the investigational drug tolvaptan treated hyponatremia -- water intoxication -- faster and more effectively than available treatments."These studies proved for the first time that hyponatremia, which is associated with poor outcomes, can be treated effectively with an oral drug that has no significant side effects," said Mihai Gheorghiade, M.D., professor of medicine at Northwestern University's Feinberg School of Medicine, who presented the results of the studies at the AHA meeting.
Hyponatremia is a relatively common electrolyte disorder. It affects a wide spectrum of patients including those with liver problems, heart failure and the elderly. It also may affect marathon runners.
Occurring in 15 to 20 percent of hospitalized patients with heart failure, hyponatremia is the opposite of dehydration. Known as "water intoxication," the condition occurs when serum sodium concentration in the blood falls to dangerously low levels causing cells in the body to stop excreting water. Normal serum sodium levels are between 135 and 145 millimoles per liter (mmol/L). Hyponatremia occurs when serum concentration drops to less than 135 mmol/L. In severe cases, it can lead to cerebral edema and even death.
Yet current therapies for hyponatremia are often ineffective and poorly tolerated. The two SALT studies will be published in the November 16 issue of the New England Journal of Medicine and presented at the AHA meeting offer promising information.
Robert Schrier, M.D., professor of medicine of the University of Colorado, Denver, and Gheorghiade and their colleagues at other institutions, found that tolvaptan, a V2-receptor antagonist developed by Otsuka Pharmaceutical Co., Ltd. and Otsuka Maryland Research Institute, Inc., began to improve patients' serum sodium levels almost immediately.
"This easy-to-administer oral drug begins to normalize serum sodium within hours. The normalization is sustained during long-term therapy," Dr. Gheorghiade said. "It is also important to note that tolvaptan was associated with an improvement in mental performance. This is important since cognition can decrease as a result of low serum sodium."
The SALT-1 and SALT-2 studies (Sodium Assessment with Increasing Levels of Tolvaptan) looked at 443 patients in the U.S. and several international sites. During the trial, about half the patients were put on the tolvaptan regimen, the other half on placebo. In both studies, patients assigned to tolvaptan had higher serum sodium concentrations at day 4 and day 30 than those in the placebo group. During the week after discontinuing the tolvaptan, hyponatremia recurred in patients.
SALT-1 and SALT-2 were identical prospective, multicenter, randomized, double-blind placebo-controlled efficacy studies. SALT-1 was conducted at 42 sites in the U.S., SALT-2 at 50 international sites.
http://www.northwestern.edu